Squarepoint’s Inovio Pharmaceuticals INO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $40K | Buy |
36,391
+11,554
| +47% | +$13.7K | ﹤0.01% | 4279 |
|
|
2026
Q1 | $43.2K | Buy |
+24,837
| New | +$40.9K | ﹤0.01% | 4146 |
|
|
2025
Q3 | – | Sell |
-32,572
| Closed | -$66.3K | – | 4650 |
|
|
2025
Q2 | $66.3K | Buy |
+32,572
| New | +$62.4K | ﹤0.01% | 4260 |
|
|
2025
Q1 | – | Sell |
-51,255
| Closed | -$93.8K | – | 4984 |
|
|
2024
Q4 | $93.8K | Sell |
51,255
-273
| -0.5% | -$1.21K | ﹤0.01% | 4711 |
|
|
2024
Q3 | $298K | Buy |
+51,528
| New | +$425K | ﹤0.01% | 3450 |
|
|
2024
Q2 | – | Sell |
-21,721
| Closed | -$301K | – | 4351 |
|
|
2024
Q1 | $301K | Buy |
+21,721
| New | +$187K | ﹤0.01% | 3384 |
|
|
2023
Q3 | – | Sell |
-1,734
| Closed | -$9.29K | – | 4010 |
|
|
2023
Q2 | $9.29K | Buy |
+1,734
| New | +$14K | ﹤0.01% | 3497 |
|
|
2022
Q3 | – | Sell |
-4,051
| Closed | -$84K | – | 3191 |
|
|
2022
Q2 | $84K | Buy |
+4,051
| New | +$114K | ﹤0.01% | 2647 |
|
|
2021
Q4 | – | Sell |
-2,286
| Closed | -$196K | – | 3326 |
|
|
2021
Q3 | $196K | Sell |
2,286
-4,784
| -68% | -$480K | ﹤0.01% | 2496 |
|
|
2021
Q2 | $786K | Buy |
+7,070
| New | +$679K | ﹤0.01% | 1813 |
|
|
2021
Q1 | – | Sell |
-6,910
| Closed | -$734K | – | 3343 |
|
|
2020
Q4 | $734K | Buy |
6,910
+4,527
| +190% | +$603K | 0.01% | 1528 |
|
|
2020
Q3 | $332K | Sell |
2,383
-292
| -11% | -$60.9K | ﹤0.01% | 1727 |
|
|
2020
Q2 | $865K | Sell |
2,675
-226
| -8% | -$36.3K | 0.01% | 1022 |
|
|
2020
Q1 | $259K | Buy |
+2,901
| New | +$179K | 0.01% | 1366 |
|
|
2019
Q3 | – | Sell |
-2,865
| Closed | -$101K | – | 2493 |
|
|
2019
Q2 | $101K | Buy |
2,865
+1,636
| +133% | +$65K | ﹤0.01% | 2226 |
|
|
2019
Q1 | $55K | Sell |
1,229
-1,022
| -45% | -$51.5K | ﹤0.01% | 2077 |
|
|
2018
Q4 | $108K | Buy |
2,251
+861
| +62% | +$52.3K | ﹤0.01% | 1789 |
|
|
2018
Q3 | $93K | Sell |
1,390
-10,701
| -89% | -$596K | ﹤0.01% | 1891 |
|
|
2018
Q2 | $569K | Buy |
+12,091
| New | +$667K | 0.01% | 1132 |
|
|
2018
Q1 | – | Sell |
-6,454
| Closed | -$320K | – | 1903 |
|
|
2017
Q4 | $320K | Buy |
+6,454
| New | +$400K | 0.01% | 1457 |
|
|
2017
Q2 | – | Sell |
-1,556
| Closed | -$124K | – | 1656 |
|
|
2017
Q1 | $124K | Sell |
1,556
-1,596
| -51% | -$127K | ﹤0.01% | 1383 |
|
|
2016
Q4 | $262K | Buy |
3,152
+1,644
| +109% | +$149K | 0.01% | 1234 |
|
|
2016
Q3 | $169K | Buy |
+1,508
| New | +$167K | 0.01% | 917 |
|
|
2016
Q1 | – | Sell |
-5,050
| Closed | -$407K | – | 1300 |
|
|
2015
Q4 | $407K | Buy |
5,050
+4,125
| +446% | +$328K | 0.04% | 646 |
|
|
2015
Q3 | $64K | Buy |
+925
| New | +$80.6K | 0.02% | 383 |
|
Other funds holding INO
JT
BCM
ACM
EP
Squarepoint's INO Position: Q2 2026 in Review
Squarepoint increased its Inovio Pharmaceuticals (INO) stake by 47% in Q2 2026, buying an estimated $13.7K and bringing the position to 36,391 shares worth $40K. The position accounts for ﹤0.01% of the portfolio, ranked #4279.
Squarepoint first reported a position in INO in Q3 2015 and has held it in 25 quarters since. The position peaked at $865K in Q2 2020. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.
- Squarepoint held 36,391 shares of Inovio Pharmaceuticals worth $40K as of Q2 2026.
- Squarepoint bought 11,554 Inovio Pharmaceuticals shares in Q2 2026, an estimated $13.7K.
- Inovio Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4279 holding.
- Squarepoint first reported a position in Inovio Pharmaceuticals in Q3 2015 and has held it in 25 quarters since.
- Squarepoint's Inovio Pharmaceuticals position peaked at $865K in Q2 2020.
- 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.
Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.